TScan Therapeutics, Inc. (TCRX) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
| Dreyfus/Laurel Funds Trust Dreyfus Core Value Fund Class I (NASDAQ: TCRX) | Delayed: 0.18 +0.01 (5.88%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.17 | 52 Week High | $26.80 | |||
| Open | $0.18 | 52 Week Low | $23.00 | |||
| Day High | $0.19 | P/E | N/A | |||
| Day Low | $0.17 | EPS | $0.00 | |||
| Volume | 497,329 | |||||
